logo

Eagle Pharmaceuticals Inc (EGRX)



Trade EGRX now with
  Date
  Headline
8/10/2020 7:17:35 AM Eagle Pharma Q2 Loss Per Share $0.02; Adj EPS $0.59
5/11/2020 6:53:11 AM Eagle Pharmaceuticals Q1 Net Loss $2.9 Mln Or $0.21/shr Vs. Net Income $9.0 Mln Or $0.64/shr Last Year
3/30/2020 6:52:16 AM SymBio Pharmaceuticals Completes Patient Enrollment In Clinical Trial For TREAKISYM Rapid Infusion In Japan
3/2/2020 6:54:38 AM Eagle Pharma Q4 Non-GAAP EPS $0.49; GAAP EPS $0.07
2/10/2020 10:00:37 AM Eagle Pharma Receives Final FDA Approval For PEMFEXY, Pemetrexed for Injection
1/13/2020 6:56:13 AM Eagle Pharma To Develop Dantrolene Sodium For Treatment Of Alzheimer's Disease In Collaboration With University Of Penn
1/9/2020 6:54:55 AM Eagle Pharma Resubmits NDA To FDA For RYANODEX For Treatment Of Exertional Heat Stroke In Addition To Body Cooling
1/7/2020 7:24:04 AM Tyme And Eagle Pharma Announce Strategic Collaboration To Advance Oral SM-88 For Patients With Cancer
1/6/2020 6:54:14 AM Eagle, NorthShore University To Study Dantrolene Sodium For Treatment Of Concussion,Other Traumatic Brain Injury
12/16/2019 6:52:21 AM Eagle Pharma: FDA Grants Orphan Drug Designation For RYANODEX For The Treatment Of Organophosphate Exposure
12/9/2019 6:53:27 AM Eagle Pharma Begins Dosing In Pilot Study For Novel Estrogen Receptor Antagonist Product Candidate
11/14/2019 6:51:42 AM Eagle Pharmaceuticals Announces Departure Of Douglas Braunstein From Board
11/12/2019 6:56:27 AM Eagle Pharma Q3 Net Loss $2.4 Ln Or $0.17/Shr Vs Income Of $14.0 Mln Or $0.91/Shr Last Year
8/5/2019 6:55:17 AM Eagle Pharma Says Clinical Development Plan To Support The Submission Of NDA For Innovative Fulvestrant Formulation
11/27/2018 6:54:59 AM Eagle Pharma Announces Positive Results Of Pre-clinical Study Conducted To Evaluate Effects Of RYANODEX In ARS
11/1/2018 6:51:23 AM Eagle Pharmaceuticals Q3 EPS $0.91 And Adjusted Non-GAAP EPS $1.18